PharmaVOICE - 
June 2005
Purchase Issue

In Every Issue
What’s New
New Healthcare-related Products, Services, and Companies PMI Appoints Task Force [...]
By
E-Media
New Electronic and Web-based Applications, Sites, and Technologies E-Media June [...]
By
On the Calendar
June 6-7 Pharmaceutical Marketers KnowledgeShare Forum 2005: Building Brand Differentiation [...]
By
Talent Pool
Pharma POOL Jean-Louis Anspach Michael R. Dornhecker Ann Willmoth Solvay [...]
By
For Art’s Sake
Each month, this department pays homage to memorable advertising and [...]
By
PharmaTrax
CME Programs Accredited by Universities and Societies Receive Preference Continuing [...]
By
PharmaOutlet
Contributed by Jim Montgomery Building Effective Communications For the Life-Sciences [...]
By

Jim Montgomery

What’s on Your Mind — Opinions
What’s on Your Mind — Opinions Opinions Blogs, which often [...]
By
Letter from the Editor
PharmaVOICE June 2005 Letter from the Editor In 1990, some [...]
By

Taren Grom, Editor

On The Cover

The Time for Transparency
June 2005 PharmaVOICE Trial transparency The Time for Transparency by Elisabeth Pena Villarroel The movement toward clinical-trial transparency and public registries is not a new idea, however, the highly publicized lawsuit by Eliot Spitzer against GlaxoSmithKline and the terms of the settlement set off a wave of activity by industry stakeholders about the transparency of [...]
By

Elisabeth Pena Villarroel

Features

David King — Regal Legal
Regal Legal By Kim Ribbink June 2005 PharmaVOICE From biotech’s early days in the mid-1980s, David R. King has played a central role in the industry, gaining a deep appreciation for science, the broad range of phases of business development, and what it takes to succeed. Years of experience representing the life-sciences industry during his [...]
By

Kim Ribbink

Ideology Vs. Science: The Stem-Cell Battle
Ideology Vs. Science: The Stem-Cell Battle By Kim Ribbink Across the globe, scientists are extolling the potential of stem- cell research to cure debilitating diseases, in spite of limits on federal funding as well as controversy surrounding the research. States and private investors have begun to step into the fray, and experts argue the importance [...]
By

Kim Ribbink

Translational Research: Making the Transition from R to D
Translational Research: Making the Transition from R to D There is a growing interest in translational research, which aims to bridge the gap between advances in basic research and the development of safe and effective therapies. June 2005 PharmaVOICE Despite increased investment in research and development and new technologies that have created novel targets, fewer [...]
By

Denise Myshko

DTC: The Next Phase
In light of FDA guidances, more public scrutiny, and trending corporate citizenship, DTC advertising is subtly shifting to direct-to-education. Direct-to-consumer advertising has been mainly focused on creating brand awareness for major blockbuster products, or creating awareness for new therapeutic categories, or both. Since 1997, when the FDA relaxed regulations on how drug companies can advertise [...]
By

Taren Grom, Editor

Risk Aversion As a Profitability-Limiting Factor in Clinical-Trial Conduct
Risk Aversion As a Profitability-Limiting Factor in Clinical-Trial Conduct What is risk? Why does it matter? Shouldn’t prudent business people try to avoid it? How does it impact the conduct of clinical trials, and can it or should it change? Timothy Pratt, Ph.D., Chief marketing officer of MedNet Solutions Inc., Minnetonka, Minn., a provider of [...]
By
Table of Contents
on the cover The time for transparency The government, medical journal editors, and general public are clamoring for the pharmaceutical industry to provide complete information about ongoing and completed clinical trials. There has been a flurry of activity, announcements, and mandates in this area, and companies are rethinking their policies on clinical-trial registries. FEATURES Translational [...]
By
FEEDBACK